World Health Organization site
Skip Navigation Links

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 12 December 2020
Main ID:  NCT02030028
Date of registration: 06/01/2014
Prospective Registration: Yes
Primary sponsor: Dana Ascherman
Public title: ACTH Gel Therapy in Rheumatoid Arthritis
Scientific title: Open Label Study to Evaluate Efficacy and Safety of Short-Term, Adjunctive Adrenocorticotropic Hormone (ACTH) Gel in Rheumatoid Arthritis
Date of first enrolment: November 2014
Target sample size: 20
Recruitment status: Recruiting
Study type:  Interventional
Study design:  Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  N/A
Countries of recruitment
United States
Name:     Laurie Hope, RN
Telephone: 412-647-2638
Name:     Laurie Hope, RN
Telephone: 412-647-2638
Name:     Larry W Moreland, MD
Affiliation:  University of Pittsburgh
Key inclusion & exclusion criteria

Inclusion Criteria:

- 18 year of age and older

- RA diagnosis by American College of Rheumatology criteria

- Active disease (CDAI > 10)

- Have received at least are biologic agent for at least 6 months

- May or may not be receiving oral daily steroids (less than or equal to 20 mg/day) of
prednisone equivalent

- No current active infections requiring antibiotics

- Patients must be on stable doses of RA therapies (e.g., methotrexate or other RA
therapies for at least 4 weeks prior to baseline visit)

Exclusion Criteria:

- Less than 18 years of age

- Unable or unwilling to give Informed Consent

- Have an active infection requiring the use of antibiotics

- Women who are pregnant

- Uncontrolled hypertension

- Abnormal renal function

- Abnormal liver function as defined by and increased Alanine transaminase (ALT,) and
aspartate aminotransferase (AST) that is greater than 5 times normal.

Age minimum: 18 Years
Age maximum: 100 Years
Gender: All
Health Condition(s) or Problem(s) studied
Rheumatoid Arthritis
Drug: ACTHAR gel
Primary Outcome(s)
Changes in Clinical Disease Activity Index [Time Frame: 12 weeks]
Secondary Outcome(s)
Change in the Disease Activity Score [Time Frame: 12 weeks]
Changes in acute phase reactants [Time Frame: 12 weeks]
Patient reported changes in fatigue [Time Frame: 12 weeks]
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results available:
Date Posted:
Date Completed:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history